Zobrazeno 1 - 10
of 17
pro vyhledávání: '"John C R, Randle"'
Autor:
Zhiwei, Wen, Veronica, Salmaso, Young-Hwan, Jung, Ngan B, Phung, Varun, Gopinatth, Qasim, Shah, Alexandra T, Patterson, John C R, Randle, Zhoumou, Chen, Daniela, Salvemini, David I, Lieberman, Gregory S, Whitehead, Tadeusz P, Karcz, Donald N, Cook, Kenneth A, Jacobson
Publikováno v:
J Med Chem
High affinity phenyl-piperidine P2Y(14)R antagonist 1 (PPTN) was modified with piperidine bridging moieties to probe receptor affinity and hydrophobicity. Various 2-azanorbornane, nortropane, isonortropane, isoquinuclidine, and ring-opened cyclopenty
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::da62c41535c927994c70d1b42266cae7
https://pubmed.ncbi.nlm.nih.gov/35113556
https://pubmed.ncbi.nlm.nih.gov/35113556
Autor:
Kenneth A. Jacobson, Donald N. Cook, Tadeusz P Karcz, John C R Randle, John M. Bennett, Varun Gopinatth, Zhiwei Wen, Ngan B. Phung, Daniela Salvemini, Young-Hwan Jung, David I. Lieberman, Veronica Salmaso, Zhoumou Chen
Publikováno v:
Journal of Medicinal Chemistry. 64:5099-5122
A known zwitterionic, heterocyclic P2Y14R antagonist 3a was substituted with diverse groups on the central phenyl and terminal piperidine moieties, following a computational selection process. The most potent analogues contained an uncharged piperidi
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c8619de0d7c2d74a8325f516dd55228e
https://doi.org/10.1021/acs.jmedchem.1c00164
https://doi.org/10.1021/acs.jmedchem.1c00164
Autor:
Zhiwei Wen, Veronica Salmaso, Young-Hwan Jung, Ngan B. Phung, Varun Gopinatth, Qasim Shah, Alexandra T. Patterson, John C. R. Randle, Zhoumou Chen, Daniela Salvemini, David I. Lieberman, Gregory S. Whitehead, Tadeusz P. Karcz, Donald N. Cook, Kenneth A. Jacobson
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::08a16138dcf66e0cf8b0d97c43fac4e0
http://hdl.handle.net/11577/3459804
http://hdl.handle.net/11577/3459804
Autor:
Young-Hwan, Jung, Veronica, Salmaso, Zhiwei, Wen, John M, Bennett, Ngan B, Phung, David I, Lieberman, Varun, Gopinatth, John C R, Randle, Zhoumou, Chen, Daniela, Salvemini, Tadeusz P, Karcz, Donald N, Cook, Kenneth A, Jacobson
Publikováno v:
J Med Chem
A known zwitterionic, heterocyclic P2Y(14)R antagonist 3a was substituted with diverse groups on the central phenyl and terminal piperidine moieties, following a computational selection process. The most potent analogues contained an uncharged piperi
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::2538a8e3308d6a52460a78072272a801
https://pubmed.ncbi.nlm.nih.gov/33787273
https://pubmed.ncbi.nlm.nih.gov/33787273
Autor:
Bambang S Adiwijaya, Eva Herrmann, Brian Hare, Tara Kieffer, Chao Lin, Ann D Kwong, Varun Garg, John C R Randle, Christoph Sarrazin, Stefan Zeuzem, Paul R Caron
Publikováno v:
PLoS Computational Biology, Vol 6, Iss 4, p e1000745 (2010)
Variants resistant to compounds specifically targeting HCV are observed in clinical trials. A multi-variant viral dynamic model was developed to quantify the evolution and in vivo fitness of variants in subjects dosed with monotherapy of an HCV prote
Externí odkaz:
https://doaj.org/article/aae165b76f2a4ad9bcccbb9fba06fbf0
Autor:
John C. R. Randle, Avidan U. Neumann, Brian Hare, Hendrik W. Reesink, Paul R. Caron, Eva Herrmann, Bambang S. Adiwijaya, Stefan Zeuzem
Publikováno v:
Antiviral therapy, 14(4), 591-595. International Medical Press Ltd
Background Telaprevir (TVR) is a hepatitis C virus (HCV) NS3.4A protease inhibitor that has exhibited antiviral activity in patients with HCV genotype 1 infection. The viral dynamics in patients dosed with TVR were compared with those reported for pa
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::34c23e7cb178b1668ce7592cf62fee93
https://doi.org/10.1177/135965350901400402
https://doi.org/10.1177/135965350901400402
Autor:
George Ku, John Pollard, Woods Wannamaker, John C. R. Randle, Peter Weber, Pamella J. Ford, Paul S. Charifson, Ursula A. Germann, Robert J. Davies, Mark N. Namchuk, Caroline Decker, Keisuke Kuida
Publikováno v:
Journal of Pharmacology and Experimental Therapeutics. 321:509-516
(S)-1-((S)-2-{[1-(4-amino-3-chloro-phenyl)-methanoyl]-amino}-3,3-dimethyl-butanoyl)-pyrrolidine-2-carboxylic acid ((2R,3S)-2-ethoxy-5-oxo-tetrahydro-furan-3-yl)-amide (VX-765) is an orally absorbed prodrug of (S)-3-({1-[(S)-1-((S)-2-{[1-(4-amino-3-ch
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::37a9c04b1f2b140f2c4400eb1c2dfa24
https://doi.org/10.1124/jpet.106.111344
https://doi.org/10.1124/jpet.106.111344
Autor:
Mirjam B. Zeisel, Jean Sibilia, Laurence A. Neff, Jean-Paul Klein, John C. R. Randle, Dominique Wachsmann
Publikováno v:
Cellular Microbiology. 6:593-598
Summary Proinflammatory cytokines such as tumour necrosis factor (TNF)-α, interleukin (IL)-1β and IL-18 are key mediators of joint inflammation during rheumatoid arthritis (RA). This chronic inflammation may result from a non-specific innate immune
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::4f6df89b214fca7dc552b2790ca2ae40
https://doi.org/10.1111/j.1462-5822.2004.00385.x
https://doi.org/10.1111/j.1462-5822.2004.00385.x
Publikováno v:
Expert Opinion on Investigational Drugs. 10:1207-1209
In recent years, several strategies that selectively inhibit pro-inflammatory cytokines, have yielded effective protein-based therapies for inflammatory disorders, validating the therapeutic hypothesis that intervention in cytokine signalling can pro
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ecc77a8226ef53b8b0bbd5d0f4ea2df2
https://doi.org/10.1517/13543784.10.7.1207
https://doi.org/10.1517/13543784.10.7.1207
Autor:
Chao Lin, Stefan Zeuzem, Brian Hare, Ann D. Kwong, Tara L. Kieffer, John C. R. Randle, Varun Garg, Eva Herrmann, Bambang S. Adiwijaya, Christoph Sarrazin, Paul R. Caron
Publikováno v:
PLoS Computational Biology, Vol 6, Iss 4, p e1000745 (2010)
PLoS Computational Biology
PLoS Computational Biology
Variants resistant to compounds specifically targeting HCV are observed in clinical trials. A multi-variant viral dynamic model was developed to quantify the evolution and in vivo fitness of variants in subjects dosed with monotherapy of an HCV prote
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::8ccd7679769853cebc9728d2abbd2e5d
http://europepmc.org/articles/PMC2855330?pdf=render
http://europepmc.org/articles/PMC2855330?pdf=render